NOVO-GLP1Agonistes du GLP-1 pour la rémission du diabète dans la chirurgie métabolique

This study is about exploring the role of GLP-1 agonists, a type of diabetes medication, in helping people with type 2 diabetes achieve remission after metabolic surgery. The goal is to enroll 126 patients, with the aim of having 100 patients complete the trial. The importance of this study lies in its potential to provide evidence for the effectiveness of GLP-1 agonists in diabetes remission after surgery, which is currently based on retrospective studies. Patients participating in this trial will receive the study drug in addition to standard care for 4 months prior to bariatric surgery. During this time, their blood sugar levels will be closely monitored through regular contact with the study team and additional lab tests. After surgery, patients will continue in the study for 2 years, with their blood sugar control managed according to current standards. The study's success will be measured by comparing changes in blood sugar control and diabetes remission rates between the group receiving the GLP-1 agonist and the control group. The primary outcome is the rate of partial remission of diabetes, defined as having an HbA1C less than 6.5%, a fasting glucose less than 125 mg/dl, or no need for diabetes medication or treatment for one year.